Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Above averageWe are a leader in the field of gene therapy, seeking to deliver to patients suffering from rare and other devastating diseases single treatments with potentially curative results. We are advancing a focused pipeline of innovative gene therapies, including our clinical candidates for the treatment of Huntington’s disease, refractory mesial temporal lobe epilepsy (“MTLE”), Fabry disease, and amyotrophic lateral sclerosis caused by mutations in superoxide dismutase 1 (“SOD1-ALS”).
In the company’s own words · 10-K filed Mar 2, 2026 · SEC EDGAR
Business segments
Q3 2025 · $3.7MThe company’s own SEC segment disclosure.
- License$3.6M97%
- Collaborative$119.0K3%
uniQure N.V. (QURE) reported revenue of $3.6M in Q1 2026 (quarter ended Mar 31, 2026), up 127% from the same quarter a year earlier. That came with a gross margin of 94% and net loss of $54M. For the full year FY2025, revenue was $16M (−41% year on year) and net income −$199M. Its largest product in Q3 2025 (quarter ended Sep 30, 2025) was License at $3.6M, 97% of the disclosed total, well ahead of Collaborative at 3.2%.
Raw charts
10 series · TTMAs reported to the SEC, without any scoring.